Clinical Trials on Usher Syndrome, Type 2A

Total 3180 results

Fred Hutchinson Cancer Center
Patient-Centered Outcomes Research Institute; American Cancer Society, Inc.

Completed

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Stanford University
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Kiadis Pharma
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Withdrawn

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

United States
Wuhan Union Hospital, China

Recruiting

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Allogeneic Hematopoietic Stem Cell Transplantation | Acute Myeloid Leukemia, Adult | Myelodysplastic Syndrome(MDS)

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia

United States
BioLite, Inc.

Not yet recruiting

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Anemia | Chronic Myelomonocytic Leukemia | Adult Myelodysplastic Syndrome

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Stichting Hemato-Oncologie voor Volwassenen Nederland
Astellas Pharma Global Development, Inc.; Deutsch-Österreichische Studiengruppe...

Active, not recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Netherlands, Belgium, Germany, Switzerland, Australia, Finland, Norway, Sweden, Austria, France, Ireland, Lithuania, Luxembourg, Spain
Washington University School of Medicine
National Cancer Institute (NCI); MacroGenics

Recruiting

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Relapsed Acute Myeloid Leukemia

United States
Aptose Biosciences Inc.

Active, not recruiting

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Nova Scotia Health Authority
Terry Fox Research Institute

Completed

AML-MDS Novel Prognostic Tests Clinical Study

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Leukemia | Myelodysplastic Syndrome

United States
CTI BioPharma
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Masonic Cancer Center, University of Minnesota

Terminated

Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myeloproliferative Disorders
European Organisation for Research and Treatment...

Completed

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

Belgium, Switzerland, Netherlands, Germany
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Anemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
St. Jude Children's Research Hospital

Recruiting

Familial Investigations of Childhood Cancer Predisposition (SJFAMILY)

Pancreatic Cancer | Hodgkin Lymphoma | Lynch Syndrome | Tuberous Sclerosis | Fanconi Anemia | AML | Non Hodgkin Lymphoma | Familial Adenomatous Polyposis | Acute Leukemia | Nevoid Basal Cell Carcinoma Syndrome | Neurofibromatosis Type 1 | Neuroblastoma | Retinoblastoma | MDS | Rhabdomyosarcoma | Von Hippel-Lindau Disease | Adrenocortical Carcinoma and other conditions

United States
Justin Watts, MD
Takeda

Completed

Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS

AML | Acute Myelogenous Leukemia | MDS | Advanced Myelodysplastic Syndromes

United States
Orlucent, Inc

Enrolling by invitation

INTER-PATHOLOGIST READER STUDY

Nevi, Dysplastic

United States
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Co., Ltd.

Terminated

Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes

Leukemia

United States
Jasper Therapeutics, Inc.

Recruiting

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

MYELODYSPLASTIC SYNDROME; MDS | ACUTE MYELOID LEUKEMIA; AML

United States
Masonic Cancer Center, University of Minnesota

Completed

Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML)

United States
NCIC Clinical Trials Group
Bayer

Completed

Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

Canada
University of Washington

Completed

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Masonic Cancer Center, University of Minnesota
Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Leukemia | Myelodysplastic Syndrome

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Terminated

Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML (MPDMDSBMT)

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders

United States
M.D. Anderson Cancer Center

Completed

Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients

Leukemia | Myelodysplastic Syndrome | Acute Myeloblastic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
PETHEMA Foundation

Completed

SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia (FLAG-IDA)

Myelodysplastic Syndrome | Acute Myeloblastic Leukemia

Spain
Wuerzburg University Hospital

Completed

Prophylactic Application of Donor-derived TCM After Allogeneic HSCT (PACT)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Germany
Cullinan Oncology Inc.

Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS) | Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States
Opna-IO LLC

Completed

A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

High-risk Myelodysplastic Syndrome (MDS) | Relapsed Acute Myeloid Leukemia (AML) | Refractory Acute Myeloid Leukemia (AML)

United States
Radboud University Medical Center

Completed

Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease (ANIDULAPK)

Leukemia | Leukemia, Myeloid, Acute | Myelodysplastic Syndrome

Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH); ViaCell

Completed

Cord Blood Expansion on Mesenchymal Stem Cells

Leukemia | Myelodysplastic Syndrome

United States
Sparrow Pharmaceuticals

Active, not recruiting

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome (RESCUE)

Cortisol; Hypersecretion | Cortisol Overproduction | Cushing's Syndrome I | Cushing Disease Due to Increased ACTH Secretion | Cortisol Excess | Ectopic ACTH Secretion

United States, Bulgaria, Romania
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

Cushing's Syndrome | Ectopic Corticotropin Syndrome | Adrenal Adenoma | Adrenal Carcinoma | AIMAH | PPNAD

Japan
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (RIVER-52)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome

Poland
Maxinovel Pty., Ltd.

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Acute Myeloid Leukemia | Leukemia | Myelodysplastic Syndrome | Relapsed/Refractory Acute Myeloid Leukemia

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia

United States
Hemavant Sciences GmbH

Terminated

A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes (Encore-MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

Korea, Republic of, United States, Taiwan, Belgium, France, Spain, Italy
University of Rochester

Completed

A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
Janssen Research & Development, LLC
argenx

Withdrawn

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

United Kingdom, Switzerland, Italy, Germany, France, Spain, Australia, Turkey, Brazil, Russian Federation, Saudi Arabia
Celgene

Completed

Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)

Leukemia, Myelomonocytic, Chronic | Myelodysplastic Syndrome

Spain
University Hospital, Grenoble

Completed

Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes (MPO-MDS-PILOT)

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

France
GlaxoSmithKline

Completed

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Myelodysplastic Syndrome

Puerto Rico, United States, Taiwan, Germany, Denmark, Hong Kong, Korea, Republic of, France, United Kingdom, Italy, Brazil
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States
Pfizer

Completed

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML)

United States

Clinical Trials on Usher Syndrome, Type 2A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations